Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients
GM2 and GM1 gangliosidoses are genetic, neurodegenerative lysosomal sphingolipid storage disorders. The earlier the age of onset, the more severe the clinical presentation and progression, with infantile, juvenile and late-onset presentations broadly delineated into separate phenotypic subtypes. Gen...
Main Authors: | Richard W.D. Welford, Herve Farine, Michel Steiner, Marco Garzotti, Kostantin Dobrenis, Claudia Sievers, Daniel S. Strasser, Yasmina Amraoui, Peter M.A. Groenen, Roberto Giugliani, Eugen Mengel |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426922000039 |
Similar Items
-
L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation
by: Beatriz Castejón-Vega, et al.
Published: (2021-11-01) -
Chitotriosidase as a biomarker for gangliosidoses
by: Sarah Kim, et al.
Published: (2021-12-01) -
Diagnosis of GM-1 gangliodosis in Cuba
by: Caridad Menéndez Saínz, et al.
Published: (2007-05-01) -
Diagnosis of GM-1 gangliodosis in Cuba
by: Caridad Menéndez Saínz, et al.
Published: (2007-05-01) -
Progressive dystonia as a presenting manifestation of GM1 gangliosidosis
by: Sahil Mehta, et al.
Published: (2019-01-01)